Lonza Specialty Ingredients, a specific division of the broader Lonza Group, was acquired by a consortium formed by Bain Capital and Cinven. This transaction focused on Lonza's specialty ingredients business rather than the entire Lonza company.
The Acquisition of Lonza Specialty Ingredients
The acquisition marked a significant strategic move for both private equity firms, Bain Capital and Cinven, as they took ownership of a key segment of Lonza's operations. This division specializes in products and solutions for various industries, including consumer health, nutrition, and industrial applications.
The transaction was valued at approximately $4.7 billion, reflecting the substantial asset size and market position of Lonza Specialty Ingredients. This acquisition highlights the continued interest of private equity firms in robust, specialized businesses within the chemicals and life sciences sectors.
Key Details of the Transaction
To provide a clear overview, here are the primary details of the acquisition:
| Detail | Description |
|---|---|
| Buyer(s) | Bain Capital & Cinven (a consortium) |
| Acquired Entity | Lonza Specialty Ingredients |
| Transaction Value | Approximately $4.7 billion |
| Type of Transaction | Acquisition of a business division |
This strategic divestment by Lonza allowed the company to focus more intently on its core pharmaceutical, biotech, and nutrition segments, while the specialty ingredients business gained new ownership with a specific investment focus from Bain Capital and Cinven.
